Loading provider…
Loading provider…
Hematology & Oncology Physician in Beverly Hills, CA
NPI: 1215966775Primary Employer
Cedars-Sinai Medical Care Foundation
cedars-sinai.org
HQ Phone
Get M.D. Omid's Phone Numberphone_androidMobile
Get M.D. Omid's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2001 - 2026
Keck School of Medicine of USC
keck.usc.edu
Medical School
Until 1999
University of Southern California/LAC+USC Medical Center
Fellowship • Medical Oncology
2004 - 2005
Fellowship • Hematology
2003 - 2004
Fellowship • Medical Oncology
2002 - 2003
University of Southern California/Los Angeles General Medical Center (USC/LA General)
Residency • Internal Medicine
1999 - 2002
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 80053Blood test, comprehensive group of blood chemicals | 256 | 717 |
| 2 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 256 | 745 |
| 3 | 84550Uric acid level, blood | 248 | 643 |
| 4 | 83615Lactate dehydrogenase (enzyme) level | 245 | 626 |
| 5 | 84100Phosphate level | 242 | 577 |
Authors: Robert Vescio, Noah Merin, Karen Reckamp, Alain Mita, Inderjit Mehmi, Akil Merchant, Justin Darrah, Ronald Paquette, Reva Basho, Jun Gong
Journal: Ann Oncol
Publication Date: 2021-10-20
Authors: Karl Lewis, Igor Puzanov, Adil Daud, Anna Pavlick, Thomas Gajewski, Antoni Ribas
Journal: Clin Cancer Res
Publication Date: 2019-11-15
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Authors: Karl Lewis, Igor Puzanov, Nikhil Khushalani, David Reardon, Peter Forsyth, Michael Postow, Hussein Tawbi, Anna Pavlick, Kim Margolin, Alain Algazi, Reena Thomas, Christopher Lao, Ahmad Tarhini, Frank Hodi, Marc Ernstoff, Michael Atkins
Publication Date: 2018-08
Lead Sponsor: NextCure, Inc.
Intervention / Treatment: DRUG: NC318
Lead Sponsor: Bristol-Myers Squibb
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: BIOLOGICAL: Ipilimumab, OTHER: Quality-of-Life Assessment, BIOLOGICAL: Recombinant Interferon Alfa-2b